267 related articles for article (PubMed ID: 3515897)
1. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
Hoeg JM; Maher MB; Zech LA; Bailey KR; Gregg RE; Lackner KJ; Fojo SS; Anchors MA; Bojanovski M; Sprecher DL
Am J Cardiol; 1986 Apr; 57(11):933-9. PubMed ID: 3515897
[TBL] [Abstract][Full Text] [Related]
2. The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia.
Hoeg JM; Maher MB; Bailey KR; Brewer HB
Atherosclerosis; 1986 Jun; 60(3):209-14. PubMed ID: 3524586
[TBL] [Abstract][Full Text] [Related]
3. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
Illingworth DR; Sexton GJ
J Clin Invest; 1984 Dec; 74(6):1972-8. PubMed ID: 6569064
[TBL] [Abstract][Full Text] [Related]
4. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
5. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
Illingworth DR
Ann Intern Med; 1984 Nov; 101(5):598-604. PubMed ID: 6567462
[TBL] [Abstract][Full Text] [Related]
6. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
8. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
[TBL] [Abstract][Full Text] [Related]
9. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Tobert JA
Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
[TBL] [Abstract][Full Text] [Related]
10. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
Bilheimer DW; Grundy SM; Brown MS; Goldstein JL
Proc Natl Acad Sci U S A; 1983 Jul; 80(13):4124-8. PubMed ID: 6575399
[TBL] [Abstract][Full Text] [Related]
11. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
[TBL] [Abstract][Full Text] [Related]
12. Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin.
East CA; Grundy SM; Bilheimer DW
Metabolism; 1986 Feb; 35(2):97-8. PubMed ID: 3633017
[TBL] [Abstract][Full Text] [Related]
13. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study.
Cummings MH; Watts GF; Umpleby M; Hennessy TR; Quiney JR; Sönksen PH
Atherosclerosis; 1995 Feb; 113(1):79-89. PubMed ID: 7755658
[TBL] [Abstract][Full Text] [Related]
14. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
[No Abstract] [Full Text] [Related]
15. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
[TBL] [Abstract][Full Text] [Related]
16. Normal cholesterol levels with lovastatin (mevinolin) therapy in a child with homozygous familial hypercholesterolemia following liver transplantation.
East C; Grundy SM; Bilheimer DW
JAMA; 1986 Nov; 256(20):2843-8. PubMed ID: 3534334
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.
Grundy SM; Bilheimer DW
Proc Natl Acad Sci U S A; 1984 Apr; 81(8):2538-42. PubMed ID: 6371816
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
Leitersdorf E; Muratti EN; Eliav O; Meiner V; Eisenberg S; Dann EJ; Sehayek E; Peters TK; Stein Y
Am J Med; 1994 May; 96(5):401-7. PubMed ID: 8192170
[TBL] [Abstract][Full Text] [Related]
19. Neomycin and plasma lipoproteins in type II hyperlipoproteinemia.
Hoeg JM; Schaefer EJ; Romano CA; Bou E; Pikus AM; Zech LA; Bailey KR; Gregg RE; Wilson PW; Sprecher DL
Clin Pharmacol Ther; 1984 Oct; 36(4):555-65. PubMed ID: 6383687
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
Thiery J; Creutzfeldt C; Creutzfeldt W; Walli AK; Seidel D
Klin Wochenschr; 1990 Aug; 68(16):814-22. PubMed ID: 2214604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
